Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT001 for Lateral Canthal Lines
NCT00968825Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Jul 2009
- Primary completion
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in lateral canthal rhytides, sponsored by Revance Therapeutics. Started Jul 2009; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT00968825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00968825.